Production (Stage)
Purple Biotech Ltd
PPBT
$2.61
-$0.09-3.33%
NASDAQ
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | 63.33% | 63.33% | 63.33% | |
| Gross Profit | -- | -63.33% | -63.33% | -63.33% | |
| SG&A Expenses | -- | -37.14% | -28.90% | -16.37% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -- | -9.48% | 6.69% | -0.88% | |
| Operating Income | -- | 9.48% | -6.69% | 0.88% | |
| Income Before Tax | -- | 23.12% | 2.54% | 8.19% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -- | 23.12% | 2.54% | 8.19% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -24.04% | -7.14% | 5.43% | |
| Net Income | -- | 23.12% | 2.52% | 8.25% | |
| EBIT | -- | 9.48% | -6.69% | 0.88% | |
| EBITDA | -- | 9.40% | -6.93% | 0.70% | |
| EPS Basic | -- | -2,504.15% | -2,639.92% | 24.31% | |
| Normalized Basic EPS | -- | 52.42% | 16.46% | 16.46% | |
| EPS Diluted | -- | -2,504.33% | -2,640.12% | 24.15% | |
| Normalized Diluted EPS | -- | 52.42% | 16.46% | 16.46% | |
| Average Basic Shares Outstanding | -- | -2.60% | -7.42% | 22.44% | |
| Average Diluted Shares Outstanding | -- | -2.60% | -7.42% | 22.44% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |